The biology and treatment of Merkel cell carcinoma:current understanding and research priorities
Standard
The biology and treatment of Merkel cell carcinoma:current understanding and research priorities. / Harms, Paul W; Harms, Kelly L; Moore, Patrick S; DeCaprio, James A; Nghiem, Paul; Wong, Michael K K; Brownell, Isaac; International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group.
In: NAT REV CLIN ONCOL, Vol. 15, No. 12, 12.2018, p. 763–776.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The biology and treatment of Merkel cell carcinoma:current understanding and research priorities
AU - Harms, Paul W
AU - Harms, Kelly L
AU - Moore, Patrick S
AU - DeCaprio, James A
AU - Nghiem, Paul
AU - Wong, Michael K K
AU - Brownell, Isaac
AU - International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group
PY - 2018/12
Y1 - 2018/12
N2 - Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with advanced age and immunosuppression. Over the past decade, an association has been discovered between MCC and either integration of the Merkel cell polyomavirus, which likely drives tumorigenesis, or somatic mutations owing to ultraviolet-induced DNA damage. Both virus-positive and virus-negative MCCs are immunogenic, and inhibition of the programmed cell death protein 1 (PD-1)-programmed cell death 1 ligand 1 (PD-L1) immune checkpoint has proved to be highly effective in treating patients with metastatic MCC; however, not all patients have a durable response to immunotherapy. Despite these rapid advances in the understanding and management of patients with MCC, many basic, translational and clinical research questions remain unanswered. In March 2018, an International Workshop on Merkel Cell Carcinoma Research was held at the US National Cancer Institute, at which academic, government and industry experts met to identify the highest-priority research questions. Here, we review the biology and treatment of MCC and report the consensus-based recommendations agreed upon during the workshop.
AB - Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with advanced age and immunosuppression. Over the past decade, an association has been discovered between MCC and either integration of the Merkel cell polyomavirus, which likely drives tumorigenesis, or somatic mutations owing to ultraviolet-induced DNA damage. Both virus-positive and virus-negative MCCs are immunogenic, and inhibition of the programmed cell death protein 1 (PD-1)-programmed cell death 1 ligand 1 (PD-L1) immune checkpoint has proved to be highly effective in treating patients with metastatic MCC; however, not all patients have a durable response to immunotherapy. Despite these rapid advances in the understanding and management of patients with MCC, many basic, translational and clinical research questions remain unanswered. In March 2018, an International Workshop on Merkel Cell Carcinoma Research was held at the US National Cancer Institute, at which academic, government and industry experts met to identify the highest-priority research questions. Here, we review the biology and treatment of MCC and report the consensus-based recommendations agreed upon during the workshop.
KW - Journal Article
KW - Review
U2 - 10.1038/s41571-018-0103-2
DO - 10.1038/s41571-018-0103-2
M3 - SCORING: Review article
C2 - 30287935
VL - 15
SP - 763
EP - 776
JO - NAT REV CLIN ONCOL
JF - NAT REV CLIN ONCOL
SN - 1759-4774
IS - 12
ER -
